Microcarrier-based clinical-grade manufacturing of therapeutic Wharton's jelly mesenchymal stromal cells.

Autor: Soder RP; Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, Kansas, USA. Electronic address: rsoder@kumc.edu., Dudley NR; Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, Kansas, USA., Dawn B; Department of Internal Medicine, Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, Nevada, USA.

Publikováno v: Cytotherapy [Cytotherapy] 2024 Dec; Vol. 26 (12), pp. 1556-1565. Date of Electronic Publication: 2024 Jul 06.

A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.

Autor: Soder RP; Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, KS, USA., Dawn B; University of Nevada, Las Vegas School of Medicine, Las Vegas, NV, USA., Weiss ML; Midwest Institute of Comparative Stem Cell Biotechnology and Department of Anatomy and Physiology, Kansas State University, Manhattan, KS, USA., Dunavin N; University of California, San Francisco, CA, USA., Weir S; Institute for Advancing Medical Innovation Medical Center, University of Kansas, Kansas City, USA., Mitchell J; Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, KS, USA., Li M; Pathology & Laboratory Medicine, Univeristy of Kansas Medical Center, Kansas City, USA., Shune L; Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA., Singh AK; Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA., Ganguly S; Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA., Morrison M; Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA., Abdelhakim H; Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA., Godwin AK; Pathology & Laboratory Medicine, Univeristy of Kansas Medical Center, Kansas City, USA., Abhyankar S; Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, KS, USA.; Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA., McGuirk J; Blood and Marrow Transplant Program, Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Suite 210, Westwood, KS, 66205, USA. jmcguirk@kumc.edu.

Publikováno v: Stem cell reviews and reports [Stem Cell Rev Rep] 2020 Oct; Vol. 16 (5), pp. 979-991.

Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.

Autor: Haixia Fu^1,2,3 (AUTHOR), Xueyan Sun^1,2,3 (AUTHOR), Ren Lin⁴ (AUTHOR), Yu Wang^1,2,3 (AUTHOR), Li Xuan⁴ (AUTHOR), Han Yao⁵ (AUTHOR), Yuanyuan Zhang^1,2,3 (AUTHOR), Xiaodong Mo^1,2,3 (AUTHOR), Meng lv^1,2,3 (AUTHOR), Fengmei Zheng^1,2,3 (AUTHOR), Jun Kong^1,2,3 (AUTHOR), Fengrong Wang^1,2,3 (AUTHOR), Chenhua Yan^1,2,3 (AUTHOR), Tingting Han^1,2,3 (AUTHOR), Huan Chen^1,2,3 (AUTHOR), Yao Chen^1,2,3 (AUTHOR), Feifei Tang^1,2,3 (AUTHOR), Yuqian Sun^1,2,3 (AUTHOR), Yuhong Chen^1,2,3 (AUTHOR), Lanping Xu^1,2,3 (AUTHOR)

Publikováno v: BMC Medicine. 2/27/2024, Vol. 22 Issue 1, p1-15. 15p. 2 Diagrams, 4 Charts, 3 Graphs.

NS309 decreases rat detrusor smooth muscle membrane potential and phasic contractions by activating SK3 channels.

Autor: Parajuli SP; Department of Pharmaceutical & Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA., Hristov KL, Soder RP, Kellett WF, Petkov GV

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2013 Apr; Vol. 168 (7), pp. 1611-25.

SK channel-selective opening by SKA-31 induces hyperpolarization and decreases contractility in human urinary bladder smooth muscle.

Autor: Soder RP; Dept. of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, Univ. of South Carolina, Columbia, SC 29208, USA., Parajuli SP, Hristov KL, Rovner ES, Petkov GV

Publikováno v: American journal of physiology. Regulatory, integrative and comparative physiology [Am J Physiol Regul Integr Comp Physiol] 2013 Jan 15; Vol. 304 (2), pp. R155-63. Date of Electronic Publication: 2012 Nov 21.